Prostate cancer urine test shows who needs treatment and when
Researchers have developed a urine test to diagnose aggressive prostate cancer and predict whether patients will require earlier treatment.
Continue readingCancer
Radioisotope couple for tumour diagnosis and therapy
Researchers from Kanazawa University have synthesised a radiotheranostic system with astatine (At-211) as the alpha-particle emitter and iodine (I-123) as the gamma-radiation source.
Continue reading 
Biomarker may help identify men with prostate cancer at greater risk of tumour metastasis
For about 90 percent of men with prostate cancer, the cancer remains localised to the primary site, resulting in a five-year survival rate of almost 100 percent. A recent report indicates that a significantly lower presence of syntaphilin (SNPH) – a mitochondrial protein within the tumour’s central core versus at the tumour’s invasive outer edge, may identify patients at increased risk of metastasis.
Continue reading 
Form drives function in cancer proliferation
A new study finds that the protein responsible for the crawling movements of cells also drives the ability of cancer cells to grow when under stress. The protein is actin, which is also a key component of the contraction apparatus of muscles throughout the body. The link between cell movement and signalling is through the cell’s actin cytoskeleton – chains of actin that dynamically assemble and disassemble to aid locomotion in cancerous and noncancerous cells.
Continue reading 
Circulating tumour DNA gives treatment options for the most common ovarian cancer type
High-grade serous ovarian cancer (HGSOC) is the most common and aggressive subtype of ovarian cancer. The HGSOC tumours consist of several heterogeneous cell populations with a large number of mutations. This genetic variability makes it difficult to find drugs that would kill all the cancer cells, and to which the cells would not become resistant during treatment. Over half of the patients diagnosed with high-grade serous ovarian cancer die within five years of diagnosis, that is, annually more than 150 000 women globally.
Continue reading 
DNA test is an effective cervical cancer screening tool for women in low-income countries
Cervical cancer is a major issue in low- and middle-income countries due to the lack of adequate screening such as routine Pap smear testing. These countries have high incidences of cervical cancer linked to human papillomavirus (HPV). Due to lack of resources for cancer screenings, these countries account for 85 percent of all cervical cancer cases.
Continue reading 
Biomarker may predict if immunotherapy is right choice for colorectal cancer patients
Foundational research by a City of Hope physician-scientist and his colleagues could one day help metastatic colorectal cancer patients decide whether to choose immunotherapy or chemotherapy as their first treatment option.
Continue reading 
Tumour-selective angiotensin blockers may improve response to cancer immunotherapy
A research team led by investigators at Massachusetts General Hospital (MGH) and the Massachusetts Institute of Technology (MIT) has found that combining a specialised version of an anti-hypertension drug with immune checkpoint blockers could increase the effectiveness of cancer immunotherapies.
Continue reading 
Urine test could prevent cervical cancer
Urine testing may be as effective as the smear test at preventing cervical cancer, according to a study published in the journal BMJ Open.
Continue reading 
Diet high in leucine may fuel breast cancer’s drug resistance
A team of researchers has discovered an unexpected relationship between levels of the amino acid leucine and the development of tamoxifen resistance in ER breast cancer.
Continue reading
